The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...
Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...
WASHINGTON — A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that senior executives at the pharma giant colluded to “deliberately slow down” clinical tests of its ...
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively, Friday after a report that the Trump administration plans to link the deaths of 25 children to COVID vaccines. Trump health officials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback